BDBM632959 US20230348453, Compound C7

SMILES Cc1csc(Cl)c1NC(=O)c1cnc(Nc2cc(nc(C)n2)N2CCN(CCO)CC2)s1

InChI Key InChIKey=JKDJAOQUTMBBQB-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 632959   

TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50:  5.02nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK1(Homo sapiens (Human))
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50:  13.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK3(Homo sapiens)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50:  35nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK3(Homo sapiens)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50:  52.3nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50: <20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7)
Affinity DataIC50:  17.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent